pembrolizumab in advanced squamous cell carcinoma of the head and neck
Published 9 years ago • 651 plays • Length 6:36Download video MP4
Download video MP3
Similar videos
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
2:37
pembrolizumab is effective in recurrent, metastatic squamous cell carcinomas of the head and neck
-
28:48
the changing treatment landscape in recurrent/metastatic squamous cell carcinoma of head & neck
-
4:14
immunotherapy for nsclc - video abstract 57550
-
5:25
dr g discusses the differences between basal cell carcinoma and squamous cell carcinoma
-
4:57
squamous cell carcinoma treatment options
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
4:06
immunotherapy for head and neck cancer treatment
-
0:51
dr. machiels on pembrolizumab and chemoradiation in hnscc
-
32:46
lenvatinib pembrolizumab in rcc, the clear trial with karine tawagi
-
0:40
dr. joshua m. bauml on pembrolizumab versus chemo in head and neck cancers
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:20
resistance to immune checkpoint blockade in patients with cscc
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:52
esmo 2022 highlights in head and neck cancer
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc